Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)
China · Delayed Price · Currency is CNY 27.56
-0.54 (-1.92%)
Apr 17, 2026, 3:00 PM CST
Aurisco Pharmaceutical Revenue
In the year 2025, Aurisco Pharmaceutical had annual revenue of 1.70B CNY with 15.03% growth. Aurisco Pharmaceutical had revenue of 460.42M in the quarter ending December 31, 2025, with 18.84% growth.
Revenue
1.70B
Revenue Growth
+15.03%
P/S Ratio
6.59
Revenue / Employee
951.50K
Employees
1,784
Market Cap
11.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.70B | 221.74M | 15.03% |
| Dec 31, 2024 | 1.48B | 213.21M | 16.89% |
| Dec 31, 2023 | 1.26B | 254.45M | 25.24% |
| Dec 31, 2022 | 1.01B | 204.71M | 25.48% |
| Dec 31, 2021 | 803.36M | 81.92M | 11.36% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Star Lake Bioscience Co., Inc.Zhaoqing Guangdong | 16.62B |
| Chengzhi | 10.87B |
| Pacific Shuanglin Bio-pharmacy | 2.38B |
| Liaoning Chengda Biotechnology | 1.39B |
| Chengdu Easton Biopharmaceuticals | 1.33B |
| Hualan Biological Vaccine | 1.20B |
| Jiangxi Fushine Pharmaceutical | 1.18B |
| Chengdu Olymvax Biopharmaceuticals | 704.16M |